ライフサイエンスコーパス: cardiac pacemaker

1 a novel, completely self-contained leadless cardiac pacemaker.

2 insights into the integrative action of the cardiac pacemaker.

3 d channel (HCN) 4 is a major subunit for the cardiac pacemaker.

4 erlying the age-related deterioration of the cardiac pacemaker.

5 uashing the age-related deterioration of the cardiac pacemaker.

6 ous renal replacement therapy, and permanent cardiac pacemaker.

7 perioperative management among patients with cardiac pacemakers.

8 hanges from 40 to 120 ms in 19 subjects with cardiac pacemakers.

9 can interfere with the function of implanted cardiac pacemakers.

10 that CaMKII plays a vital role in regulating cardiac pacemaker activity mainly via modulating I(Ca, L

11 r times to activate and sustain the putative cardiac pacemaker activity of the terminal chamber syner

12 siological processes, including neuronal and cardiac pacemaker activity, vascular smooth muscle contr

13 types, as HCN and TTC channels also mediate cardiac pacemaker activity.

14 ) that contributes pivotally to neuronal and cardiac pacemaker activity.

15 to the diastolic depolarization critical for cardiac pacemaker activity.

16 HCN4 function and could cause a reduction of cardiac pacemaker activity.

17 he inward and outward channels that underlie cardiac pacemaker activity.

18 atrial node (SAN) to function as the leading cardiac pacemaker and the atrioventricular (AV) junction

19 f the 1998 guideline for the implantation of cardiac pacemakers and antiarrhythmia devices.

20 e of moderate intensity in all patients with cardiac pacemakers and focally increased uptake of mild

21 Worldwide, nearly 3 million patients have cardiac pacemakers and more than 300,000 have implantabl

22 Cardiac pacemakers and reservoirs of central venous line

23 ectromagnetic interference may occur between cardiac pacemakers and wireless hand-held (cellular) tel

24 Conventional cardiac pacemakers are associated with several potential

25 Cardiac pacemakers are limited by device-related complic

26 tion age of various Pu materials (Pu powder, cardiac pacemaker battery, (242)Cm heat source, etc.) wa

27 ble, coupled-clock system that drives normal cardiac pacemaker cell automaticity.

28 s) from sarcoplasmic reticulum (SR) regulate cardiac pacemaker cell function by activation of electro

29 tracellular Ca(2+) cycling dynamics regulate cardiac pacemaker cell function on a beat-to-beat basis

30 rate that a Pak1 signaling pathway exists in cardiac pacemaker cells and that this novel pathway play

31 These findings suggest that cardiac pacemaker cells are physically segregated and mo

32 Cardiac pacemaker cells autonomously generate electrical

33 Sinoatrial node myocytes act as cardiac pacemaker cells by generating spontaneous action

34 Cardiac pacemaker cells create rhythmic pulses that cont

35 support the idea that Ca(2+) regulates CL in cardiac pacemaker cells on a beat-to-beat basis, and sug

36 echanisms driving heart rate acceleration in cardiac pacemaker cells remain incompletely understood.

37 many natural and technological systems, from cardiac pacemaker cells to coupled lasers.

38 In cardiac pacemaker cells, hetero-tetramer GIRK1/4 channel

39 ls modulate the firing rates of neuronal and cardiac pacemaker cells.

40 f several types of ion channels expressed in cardiac pacemaker cells.

41 The cardiac pacemaker controls the rhythmicity of heart cont

42 ilitating diseases, including heart failure, cardiac pacemaker defects, muscle wasting, and osteoporo

43 ld be used as a pulse generator, mimicking a cardiac pacemaker delivering pulses of 10muA for 0.5ms a

44 tients (15%) required the use of >1 leadless cardiac pacemaker during the procedure.

45 ells (such as stem cell-derived neuronal and cardiac pacemakers) for gene- and cell-based therapies.

46 nt and is crucial for both basal and reserve cardiac pacemaker function.

47 hMSCs transfected with a cardiac pacemaker gene, mHCN2, by electroporation expres

48 Thyroid hormone regulation of the cardiac pacemaker gene, the hyperpolarization-activated

49 ss rate was 94%: for patients whose leadless cardiac pacemaker had been implanted for <6 weeks (acute

50 tely self-contained, single-chamber leadless cardiac pacemaker has shown to be safe and feasible.

51 pacemaker was developed, the basic design of cardiac pacemakers has remained relatively unchanged ove

52 Leadless cardiac pacemakers have emerged as a safe and effective

53 multicenter trials, who received a leadless cardiac pacemaker implant and who subsequently underwent

54 chronic retrieval (>6 weeks) of the leadless cardiac pacemaker in humans.

55 dy, we implanted an active-fixation leadless cardiac pacemaker in patients who required permanent sin

56 e) with a mean age of 63 years and permanent cardiac pacemakers in situ were studied.

57 921) was 72% compared with 92.5% for the 179 Cardiac Pacemaker, Inc.

58 Proper expression and function of the cardiac pacemaker is a critical feature of heart physiol

59 A leadless cardiac pacemaker (LCP) system was recently introduced t

60 The leadless cardiac pacemaker met prespecified pacing and sensing re

61 ytes were used as two- and three-dimensional cardiac pacemaker models.

62 It is unknown whether cardiac pacemakers or permanent central venous catheters

63 excitable cells modulate the excitability of cardiac pacemaker preparations by two distinct mechanism

64 irected differentiation into specific mature cardiac, pacemaker, smooth muscle, and endothelial cell

65 A cardiac pacemaker was implanted during the first two wee

66 atic and potentially lifesaving therapies of cardiac pacemakers while mitigating many of the risks as

67 crossover study, we tested 980 patients with cardiac pacemakers with five types of telephones (one an